Cargando…

Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience

BACKGROUND: Cefiderocol is a novel siderophore cephalosporin with promising activity against most carbapenem-resistant Gram-negative bacteria (CRGNB). However, extensive postmarketing experiences are lacking. This study aimed to analyse the early experience on cefiderocol postmarketing use at three...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piccica, Matteo, Spinicci, Michele, Botta, Annarita, Bianco, Vincenzo, Lagi, Filippo, Graziani, Lucia, Faragona, Alessandro, Parrella, Roberto, Giani, Tommaso, Bartolini, Andrea, Morroni, Gianluca, Bernardo, Mariano, Rossolini, Gian Maria, Tavio, Marcello, Giacometti, Andrea, Bartoloni, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631827/ https://www.ncbi.nlm.nih.gov/pubmed/37807834 http://dx.doi.org/10.1093/jac/dkad298

Ejemplares similares

High-dose steroids for the treatment of severe COVID-19
por: Piccica, Matteo, et al.
Publicado: (2021)

Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020
por: Lagi, Filippo, et al.
Publicado: (2020)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
por: Kaye, Keith S., et al.
Publicado: (2023)

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
por: Oueslati, Saoussen, et al.
Publicado: (2022)

Arbo-Score: A Rapid Score for Early Identification of Patients with Imported Arbovirosis Caused by Dengue, Chikungunya and Zika Virus
por: Vellere, Iacopo, et al.
Publicado: (2020)

Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022
por: Coppi, Marco, et al.
Publicado: (2022)

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
por: Matsumoto, Shuhei, et al.
Publicado: (2020)

Low risk of serological cross-reactivity between dengue and COVID-19
por: Spinicci, Michele, et al.
Publicado: (2020)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
por: Sajib, Monirul I., et al.
Publicado: (2023)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

AIDS patient with severe T cell depletion achieved control but not clearance of SARS‐CoV‐2 infection
por: Spinicci, Michele, et al.
Publicado: (2021)

Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy
por: Manciulli, Tommaso, et al.
Publicado: (2022)

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany
por: Ghebremedhin, Beniam, et al.
Publicado: (2021)

Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy
por: Lagi, Filippo, et al.
Publicado: (2021)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Pyemotes ventricosus Dermatitis: A Case Report and an Extensive Review of Outbreaks and Clinical Cases
por: Vellere, Iacopo, et al.
Publicado: (2022)

Zika Virus: a Review from the Virus Basics to Proposed Management Strategies
por: Zammarchi, Lorenzo, et al.
Publicado: (2016)

The Importance of Updating and Continuous Education on Imported Emerging Diseases
por: Zammarchi, Lorenzo, et al.
Publicado: (2017)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
por: Palombo, Marta, et al.
Publicado: (2023)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
por: Mabayoje, Diana A, et al.
Publicado: (2021)

1034. FebriDx use in Immunocompromised Patients in a Real-World Hospital Setting during the second (COVID-19) wave in Italy
por: Lagi, Filippo, et al.
Publicado: (2021)

Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol
por: Vellere, Iacopo, et al.
Publicado: (2021)

In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
por: Quirino, Angela, et al.
Publicado: (2023)

Soccer in the time of COVID-19: 1 year report from an Italian top league club, March 2020–February 2021
por: Spinicci, Michele, et al.
Publicado: (2021)

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6596gvlqs3ult792u63rssrerf